Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

Breast cancer is one of the most common cancers in women around the globe Tamoxifen is
used for the last 40 years as an endocrine therapy for breast cancer. This resulted in the …

DAXX displays complex biological functions. Remarkably, DAXX overexpression is a
common feature in diverse cancers, which correlates with tumorigenesis, disease …

Breast cancer develops in the mammary glands during mammalian adulthood and is
considered the second most common type of human carcinoma and the most incident and …

Purpose: PARP inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast
and ovarian cancers, but resistance due to reversion of mutated BRCA1/2 and other …

High invasive capacity and acquired tyrosine kinase inhibitors (TKI) resistance of kidney
renal clear cell carcinoma (KIRC) cells remain obstacles to prolonging the survival time of …

Homeobox genes function as master regulatory transcription factors during development,
and their expression is often altered in cancer. The HOX gene family was initially studied …

Estrogen Receptor is the driving transcription factor in about 75% of all breast cancers,
which is the target of endocrine therapies, but drug resistance is a common clinical problem …

The elucidation of molecular events that confer tamoxifen resistance to estrogen receptor α
(ER) positive breast cancer is of major scientific and therapeutic importance. Here, we report …

Abstract Background Non-coding RNAs are now recognized as fundamental components of
the cellular processes. Non-coding RNAs are composed of different classes, including …